Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMEY-U52
- Development stage
- Preclinical
- Lead developer
- Jianmin Pharmaceutical Group
- Modality
- Small Molecules
01
Overview
JMEY-U52 is a pediatric drug candidate currently under development by Jianmin Pharmaceutical Group. It is positioned as an expectorant, intended to facilitate the clearance of mucus from the respiratory tract in children. The compound is being developed through the Jianmin Pediatric Research Institute and is presently in the Preclinical and CMC (Chemistry, Manufacturing, and Controls) stage. While specific details regarding its molecular target or chemical composition have not been publicly disclosed, it is part of a specialized pipeline of pediatric-focused medications (identified by the 'JMEY' prefix) aimed at addressing respiratory conditions in younger populations.
Beyond the preview
Go deeper on JMEY-U52.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMEY-U52.